BD Becton Dickinson and Company Reports Fourth Quarter and Full Fiscal Year 2024 Financial Results
Intellectia.AI2024-11-07
BD (Becton, Dickinson and Company) Reports Fourth Quarter and Full Fiscal Year 2024 Financial Results
Franklin Lakes, N.J., Nov. 7, 2024 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, announced its financial results for the fourth quarter and the full fiscal year ending September 30, 2024.
Key Financial Metrics
| Financial Metric | Q4 2024 | Q4 YOY Growth | Consensus Estimates | FY24 | FY24 YOY Growth | Consensus Estimates |
|---|---|---|---|---|---|---|
| Revenue (B) | $5.4 | 6.9% | $5.38 | $20.2 | 4.2% | $20.16 |
| EPS (Adjusted) | $3.81 | 173.6% | $3.77 | $13.14 | 7.6% | $13.11 |
Interpretation: Becton, Dickinson and Company reported Q4 revenue of $5.4 billion, surpassing Wall Street's consensus estimate of $5.38 billion and reflecting a year-over-year growth of 6.9%. The adjusted EPS for the quarter was $3.81, exceeding the estimate of $3.77, showing significant improvement from the previous year.
Segment Revenue Performance
| Business Segment | Revenue Performance |
|---|---|
| BD Medical | Strong growth led by MMS with double-digit infusion growth driven by BD Alaris™. |
| BD Life Sciences | Growth driven by strong Specimen Management and double-digit growth in BD MAX™ IVD. |
| BD Interventional | Organic growth with notable performance in Infection Prevention and Phasix™. |
Interpretation: BD Medical segment led by Medication Management Solutions demonstrated substantial growth due to strong infusion sets' utilization. BD Life Sciences saw robust performance in Integrated Diagnostic Solutions driven by volume strength. The BD Interventional segment showed broad organic growth, with significant contributions from Infection Prevention and hernia solutions.
Key Developments and Operational Highlights
- Completion of Edwards Lifesciences' Critical Care acquisition, enhancing BD's monitoring technology capabilities.
- Celebrated 75 years of U.S. manufacturing at the Columbus, Nebraska site, increasing syringe production.
- New product announcements across several business units, advancing AI-enabled clinical tools, and expanding the BD Neopak™ range.
Comments from Company Officers
Tom Polen, BD's chairman, CEO, and president, emphasized the advancement in BD's growth strategy, focusing on technology-driven healthcare solutions and successful integration of acquisitions. This strategy, supported by BD Excellence system, has facilitated margin expansion and enhanced the company's financial outcomes.
Forward Guidance
BD provided revenue guidance for FY25, expecting an 8.9% to 9.4% GAAP growth and adjusted EPS between $14.25 to $14.60, reflecting approximately 10% growth at the midpoint. This guidance anticipates challenges such as market dynamics in China and Biosciences.
Stock Price Movement
Following the earnings release, BD's stock experienced a positive movement, recording a 1.16% increase.
In summary, BD's strong financial performance in Q4 and FY24 reflects its strategic initiatives focusing on higher-growth healthcare sectors and its capability to innovate and adapt in a shifting global health landscape. The company's forward-looking guidance suggests optimism for 2025, aligning with its growth trajectory and stakeholder value creation.
Share